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ABSTRACT 
The article focuses on analysis of the main system types to deliver aerosol 
medication. They have their advantages and disadvantages and used in 
different age range patient. The main specific features of using different 
inhalers and medications have been determined.  The algorithm to choose 
an inhaler type for children with bronchial asthma has been suggested 
which can be which can be insured by pharmacists to provide 
pharmaceutical care. The content analysis of the Instructions to use 
inhalation medications has been done. The need to enlarge the given 
information and to provide schematic addition of the inhalation procedure 
to the instruction has been defined. 
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Introduction. New systems to deliver medications while treating bronchopulmonary diseases 
have become very popular today. Global Initiative for Asthma recognizes inhalation therapy as that 
which has the leading role to treat bronchial asthma (BA). Due to this system of delivering, medication 
gets to the target organ and causes no side reactions in other body systems. Practicing inhalation 
therapy in-patients and out-patients leads to decrease of bronchial asthma recurrence rate, 
hospitalization, and also improve patent’s and their families’ quality of life [1]. 
Although the national and international standards and protocols of BA treatment unify the approach 
of assessing and treating patients, but it is not always possible to control the clinical disease manifestations in 
practice. Patients’ mistakes while using an inhaler are one of the reasons of uncontrolled BA frequency 
because wrong technique cannot provide a delivery of the necessary medication dose to the lungs [1,2]. 
At present it is essential for medical officers and pharmacists to teach patients the inhalation 
technique. The foreign professional literature states that 88% patients with BA make at least one 
mistake while using an inhaler. According to the research taken in Ukraine 92% of children break do 
not follow the instructions of inhalation technique or even do it wrong [3,4]. 
Nowadays the pharmaceutical market of Ukraine offers a wide range of medications and medical 
products for inhalation therapy. The choice of the inhaler for children should depend on patients’ cognitive 
abilities. So, children under 3, as a rule, cannot perform specific breathing maneuvers, therefore they are 
recommended to use a facial mask for inhalation. The best way is to teach children how to use a 
mouthpiece because breathing through this device increase the level of medications depositing in lungs [5]. 
Inhalation therapy for children with BA has been researched by many scientists. The authors 
have studied efficiency of delivering inhalation medications particularly to children with BA with the 
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help of different inhalers. However, there is no research done on the instruction content of medical use 
of inhalation medications for children with BA.  
The purpose of the research. To study different types of devices and the principles of their 
work for inhalation therapy and to analyze the instructions content of medication use in inhalation for 
children with BA are our purpose of the research.  
The materials and methodology of the research. The national and foreign professional literature 
has been studied; the content of the instructions how to use medications in medical practice to treat children 
with BA has been analized. The method of systematic structural analysis has been applied.  
The research results. Now the pharmaceutical market of Ukraine can offer many different 
inhalation devices. Unfortunately, pharmacists are said to have poor knowledge of product range, their 
use and care. They also note that there is lack of reliable professional source of information which can 
help them to learn the main characteristics of inhalation devices.  
Currently there are several system types to deliver aerosol medication: 
1. Metered-dose Aerosol Inhaler (MAI). It was introduced into practice in 1950s as the first 
portable multi-dose inhaler. Medications inhaled with the help of MAI include 
chlorofluorohydrocarbon propellant (CFH) and hydrofluoric alkane (HFA). One of the specific 
features to consider is that at the first use and after a long break before using the inhaler one should 
«refresh» it (spray 2-4 doses in the air).  
To avoid the problems of synchronization while using MAI, it is recommended to use an 
intermediate reservoir which connects the inhaler and the patient’s respiratory tracts – a spacer. 
Spacers are divided into 2 types: small (130-300 ml) and big (600-800 ml) volume. Some of them are 
supplied with a whistle which signals at a rather speedy inhale. It is very convenient because the 
patient can practice inhaling technique and take the inhale which will not produce a sound signal. 
Spacers are used for several months, hence they need hygienic processing. Spacers are washed in mild 
solution of dishwashing liquid and dried naturally. Manufactures recommend disinfecting spacers 1 
time per week or 1 time per month [6, 8]. 
2. Breath-activated Inhaler (BAI) is an inhalation device which can help to avoid the problem 
of insufficient coordination of inhale to the inhaler activation while using standard MAI.  
3. Powder Inhaler (PI). It is a breath-activated inhaler type that has a small size. Patients 
should be taught to exhale to the level of functional lungs residual volume before starting inhalation. It 
is forbidden to exhale into the inhaler as one can blow out the prepared dose of medication from the 
inhaler. The most frequent mistake while using such type of inhalers is when patients do not take a 
deep exhale before inhalation [6-8].  
4. Nebulizer is a device to generate aerosol which contains dispersed particles. Its advantage 
is that it can disperse high doses of medication which MAI and PI cannot produce. Many nebulizers 
are supplied with facial masks and can be used for children under 2. In case the patient cannot tolerate 
the mask, it is recommended to use a mouthpiece for inhalation [9].  
 
Table 1. Advantages and disadvantages of different inhaler devices 
Inhaler type Advantages Disadvantages 
1 2 3 
MAI - portability; 
- convenience;  
- high speed of inhalation procedure;  
- no risk of contamination; 
- low price 
- synchronizing the patient’s inhale and 
the inhaler’s activation; 
- high speed of aerosol spraying (over 
30 m/s);  
- low depositing in lungs and high – in 
oropharynx; 
- irritant effect of the propellant to 
mucosa of respiratory tracts (RT);  
- freon can cause cough at a «cold 
effect»; 
- difficulty to determine the medication 
dose leftover 
Breath-
activated 
Inhaler 
- simple inhalation technique; 
- high lungs deposition 
- if breath-activated, the speed of 
inhalation flow is not controlled 
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Continuation of table 1. 
1 2 3 
PI - compact; 
- medication particles are constantly 
inhaled due to the patient’s inhaling; 
- high speed of inhalation procedure;  
- some PI are supplied with a dose 
meter 
- loss of some medication in the inhaler; 
- high depositing in oropharynx; 
- efficiency decrease of some powders 
at storage; 
- irritant effect of powder to mucosa of 
RT which causes cough and 
bronchospasm 
Nebulizer - simple technique; 
- economy of medication use; 
- no necessity to synchronize the 
patient’s inhale and inhalation; 
- aerosol cloud has no propellants 
which cause RT; 
-  creating higher concentration of 
medications in RT 
- need of energy source; 
- inhalation time can increase; 
- a risk of bacterial contamination in 
case of poor hygiene; 
- high price 
We have analyzed the principles of using different types of inhaler devices and have identifies 
a several specific features. They relate to the start of inhaler work, care rules, and also patient’s 
activities after finishing inhalation (table 2).  
 
Table 2. Specific features of different inhaler types for the pharmacist to consider while selling 
medications 
Inhaler 
type 
Specific features 
MAI - M which is delivered by the inhaler to the mouth can be tasteless or even felt in the 
mouth 
- it is necessary to keep, disinfect and «refresh» the inhaler according to the 
manufacture’s instruction 
- if inhalation glucocorticosteroids (IGCS) prescribed, it is necessary to use a spacer 
or a valve spacer 
- it is necessary to rinse the mouth after IGCS inhalation even while using a spacer 
- spacer should be disinfected according to the instruction 
BAI - the patient can define if the medications dose is received by the taste or sound which 
confirms medication release 
PI - before inhaling medications with the help of PI it is necessary to exhale without the 
inhaler 
- first, it is necessary to take a strong inhale rather than gradually increase inhale 
speed 
Nebulizer - if it is impossible to inhale through the mouthpiece, one should use a facial mask 
- it is necessary to rinse Nebulizer after every use  
- a patient should be informed that term of nebulizer change is determined in the 
instruction  
 
Having systemized the obtained results we have developed an algorithm of choosing an 
inhaler type for the children with BA (Figure 1). One can see that this algorithm supposes the choice 
of the inhaler according to the age and cognitive characteristics of the child.  
Patients have a right to be well informed of medication use by the doctor or pharmacists, or 
any other information source including medication instruction (further Instruction). The instruction 
should contain the simplified data which can be understood by the patient themselves or with the 
doctor’s or pharmacist’s help to get all necessary information. We have analyzed the content of 
medication instructions which are used for inhalation therapy of children with BA [10, 11]. The 
sample includes 25 medications, the most of which are represented by the following medications, such 
as powder (36%) and aerosol (32%) (Figure 2). 
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Fig. 1. Algorithm to choose the inhaler type for children with BA 
 
Fig. 2. Distribution of medication forms used in inhalation therapy of children with BA 
In general, the Instruction section «Directions for use and dose» of the medication group under 
analysis has the following structure: 
1. Dose 
2. Inhaler testing 
3. Inhaler use 
4. Cleaning 
5. Notes (recommendations).  
However, the Instruction of medication for inhalation therapy to use in Nebulizer includes 
information about the solvent and extra components of the inhaler (Table 3). 
The pharmacists who sell medications and / or medical devices 
Determining patient’s age 
Under 3  
3-6 years olds 
Above 6 
➢ MAI+spacer with 
a mask 
Alternative 
➢ Nebulizer with a 
mask 
➢ MAI+spacer 
with a mouthpiece 
Alternative 
➢ Nebulizer with a 
mouthpiece 
➢ PI 
➢ BAI 
➢ MAI+spacer with 
a mask 
Alternative 
➢ Nebulizer with a 
mouthpiece 
For hyperactive 
children 
➢ MAI+spacer with 
a mouthpiece 
Result – choosing the most optimal device to deliver inhalation 
medication, increasing the level of treatment efficiency; 
enhancing motivation to sustain treatment 
 
Suspension, 16% 
Aerosol, 32% 
Solution, 12% 
Powder, 36% 
Capsules, 4% 
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Table 3. The structure characteristic of medication instructions used in inhalation therapy of 
children with BA 
Instruction 
subsection 
Description Medications which include 
Inhaler testing Peculiarities of the first 
inhalation start and every next 
use  
Airtek, Budesonide-inteli, Ventolin Evohaler, 
Pulmicort turbuhaler, Salbutamol, Seretide 
Diskus, Seretide Evohaler, Symbicort 
turbuhaler, Flixotide Evohaler, Formoterol 
easyhaler, Fortex 
Inhaler use Stage-by-stage process of 
inhalation with set timing 
Airtek, Ventolin Evohaler, Zafiron, Pulmicort 
turbuhaler, Salbutamol, Seretide Diskus, 
Seretide Evohaler, Symbicort turbuhaler, 
Flixotide Evohaler, Flutixon, Formoterol 
easyhaler, Fortex 
Cleaning Description of process and 
cleaning, and also its 
frequency  
Airtek, Budesonide-inteli, Ventolin Evohaler, 
Zafiron, Pulmicort turbuhaler, Salbutamol, 
Seretide Diskus, Seretide Evohaler, Symbicort 
turbuhaler, Flixotide Evohaler, Flutixon, 
Formoterol easyhaler, Fortex 
Notes 
(recommendations) 
Rinse your mouth or throat 
after inhalation 
Airtek, Budesonide-inteli, Pulmicort 
turbuhaler, Flixotide Evohaler 
Use a spacer Ventolin Evohaler, Salbutamol, Flixotide 
Evohaler 
Test the first several 
inhalations in front of the 
mirror to control the technique 
Airtek, Ventolin Evohaler 
Tasteless or medication taste 
in the mouth 
Pulmicort turbuhaler 
For nebulizer therapy  
Solvent Saline (0,9%) and its 
necessary volume  
Berodual, Pulmicort 
Solutions for inhalation Pulmicort 
Undiluted solution Ventolin nebules, Nebutamol 
Nebulizer use Stage-by-stage process of 
inhalation 
Ventolin nebules, Nebufluzon, Flixotide 
nebules 
Cleaning Rinse Nebutamol, Pulmicort 
No information  Berodual, Ventolin nebules, Nebufluzon, 
Flixotide nebules  
Notes 
(recommendations) 
Use a mouthpiece or a mask Berodual, Ventolin nebules, Nebutamol, 
Nebufluzon, Pulmicort, Flixotide nebules  
Use face lotion or rinse it 
thoroughly 
Nebufluzon, Pulmicort, Flixotide nebules  
 
Having analyzed the content of Instructions, we can state that the information as to using 
inhalation medication is given fully in every instruction. 8 medications (32%) have the subpart 
«Inhaler Use» supplied with a scheme of inhalation stages. Providing the patient the information in an 
easy way is convenient and necessary for the pharmacists to raise sanitary awareness. Much 
information given in the instruction, a number of problems as to use the researched medications, for 
children in particular still remain. Thus, only16% of Instructions have the subpart «For Children» 
which focuses that small children need help and it may be necessary for adults to assist children while 
using an inhaler or learn the technique of inhalation together. The rules of holding the inhaler are 
described for older children, e.g. the instructions to use Ventolin Evohaler, Salbutamol, and Seretide 
Evohaler. Although all 25 researched medications are used in pediatric practice.  
Medications for Nebulazer inhalation have no schematic instruction, and the algorithm of 
providing the information as to medication use is rather short.  
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Conclusions. 
1. The main system types of delivering aerosol medication have been analyzed. They have 
their advantages and disadvantages and used for different age range patients.  
2. The main specific features of using different inhalation medications and medical products 
have been established. The pharmacist should draw patient’s attention to these features if the device is 
for children with BA.  
3. The algorithm of choosing the inhaler for children with BA has been suggested which can 
be insured by pharmacists to provide pharmaceutical care. 
4. We have analyzed the content of Instructions and we can state that the information as to using 
inhalation medication in the subpart «How to use and doses» is given in a different way and needs 
additions for some medications.  Thus, only 32% of Instructions is supplied with a scheme to follow the 
inhalation procedure stages and only16% of Instructions have the subpart «For Children» which 
emphasizes necessity for adults to assist children to learn the technique of inhalation by the children.  
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